Cipla plans deeper push in domestic market and chronic therapies over next 2–3 years

Cipla's incoming MD and CEO-designate, Achin Gupta, outlined a two-to-three-year strategy focusing on deepening the domestic market presence and pursuing selective inorganic growth and innovation. The company aims to strengthen its respiratory leadership and achieve similar dominance in cardiometabolic diseases and obesity, with a near-term focus on the GLP-1 weight-loss segment through its partnership with Eli Lilly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0Zv75Wb
via IFTTT